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Abstract
Purpose
To evaluate factors affecting the use and delay8 weeks of adjuvant chemotherapy and
the impact of chemotherapy use and delay on survival.
Methods
Between 2005 and 2012, consecutive patients with stage II and III colorectal cancer who
were treated with major curative resection were enrolled.
Results
Among 750 patients with stage II (n = 318) and III (n = 432) disease, 153 (20.4%) did not
receive chemotherapy. Among 597 patients with adjuvant chemotherapy, 31 (5.2%) began
chemotherapy 8 weeks or more after surgery. Factors associated with not receiving chemo-
therapy were: age80 years (hazard ratio [HR] = 5.2), American Society of Anesthesiolo-
gists score3 (HR = 1.9), underlying cerebrovascular disease (HR = 1.7), stage II disease
(HR = 2.0), presence of postoperative complications (HR = 2.2), or intensive care unit
admission (HR = 2.4). Factors associated with chemotherapy delay8 weeks were: male
sex (HR = 4.2), rectal primary cancer (HR = 5.4), or presence of postoperative complica-
tions (HR = 2.5). Independent prognostic factors for overall survival included TNM III stage
(HR = 2.04) and chemotherapy delay8 weeks (HR = 0.39) or <8 weeks (HR = 0.22). Inde-
pendent prognostic factors for recurrence-free survival were TNM III stage (HR = 2.26) and
chemotherapy delay <8 weeks (HR = 0.35).
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Conclusions
Postoperative complications were associated with both lack of and delayed chemotherapy.
Timely initiation of chemotherapy, defined as <8 weeks, was a favorable prognostic factor
for overall and recurrence-free survival. To increase the proportion of patients receiving
chemotherapy and timely initiation of chemotherapy, surgical complications should be mini-
mized after curative resection.
Introduction
Curative surgical resection is the primary treatment modality for colorectal cancer. After resec-
tion, adjuvant chemotherapy is performed to reduce the risk of metastasis and recurrence [1].
Although quantifying the oncologic benefits of adjuvant chemotherapy is difficult, chemother-
apy with fluorouracil and folinic acid improves survival by 3.6% in patients with stage II colo-
rectal cancer [2]. According to a meta-analysis by Dube et al.[3], adjuvant chemotherapy with
fluorouracil improved survival by 5% for patients with Dukes C colon cancer and adjuvant che-
moradiation therapy increased survival by 9% for patients with Dukes B and C rectal cancer. In
2011, only 64% of patients with stage III colon cancer received adjuvant chemotherapy in the
United States [4]. Use of chemotherapy is associated with age, race, underlying disease, marital
and economic status, and occurrence of postoperative complications [5].
The impact of delayed chemotherapy on survival is controversial because of the paucity of
high-level evidence. Factors associated with chemotherapy delay are age, race, postoperative
recovery, underlying disease, histologic grade, and marital status [6].
Although current National Comprehensive Cancer Network (NCCN) guidelines recom-
mend adjuvant chemotherapy for people with stage II and III colorectal cancer after surgery [7,
8], no guidelines have been established for the time to chemotherapy initiation. Most clinical
trials favor initiation of adjuvant chemotherapy for colon cancer within 6 to 8 weeks after sur-
gery [9, 10]. Thus, a randomized trial to evaluate the impact of delayed chemotherapy on
patient survival would be unethical.
To date, the reasons for use and delay of adjuvant chemotherapy have not been extensively
studied and the association between chemotherapy delay and oncologic outcomes remains
unclear. This study aimed to evaluate factors affecting the use and delay8 weeks of chemo-
therapy after colorectal cancer surgery and the impact of chemotherapy use and delay on onco-
logic outcomes.
Methods
Patients
This retrospective cohort study was performed at a tertiary referral center following the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines
[11]. All clinical investigations were conducted according to the principles expressed in the
Declaration of Helsinki and were approved by the Institutional Review Board of Wonju Sever-
ance Christian Hospital (YWMR-14-5-099). All participants provided their written informed
consent to participate in this study and the ethics committee approved this consent procedure.
Informed consent was obtained from all patients before surgery. Between 2005 and 2012, 750
consecutive patients undergoing major resection for stage II and III colorectal cancer were
enrolled. Eligibility criteria were histologically confirmed colorectal cancer and major colorec-
tal resection with curative intent. Patients with stage I and IV disease and those undergoing R2
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resection for macroscopic residual disease or nonresectional procedures for colorectal cancer
were excluded.
Study endpoints
The primary endpoint was identifying factors affecting use and delay8 weeks of adjuvant
chemotherapy after colorectal cancer surgery. The secondary endpoint was the impact of use
and delay of chemotherapy8 weeks on oncologic outcomes.
Preoperative chemoradiation therapy
Patients with clinical stage T3 or T4 and/or node-positive rectal cancer underwent preoperative
chemoradiation therapy. A long course schedule was used and total radiation dose was 50.4
Gy. Radiation was delivered to the entire pelvis (45 Gy in 25 fractions) with a boost to the pri-
mary tumor (5.4 Gy in 3 fractions) over 5 weeks. Intravenous chemotherapy (425 mg/m2
5-fluorouracil and 20 mg/m2 leucovorin) was administered during weeks 1 and 5 of radiation
therapy.
Surgery, adjuvant therapy, and follow-up
After standardized preoperative preparations, standard surgical procedures were performed.
Complete mesocolic excision for colon cancer and total mesorectal excision for rectal cancer
were performed using standard surgical procedures.
After recovery from surgery, all patients with stage II and III disease were recommended to
receive chemotherapy according to NCCN guidelines. All cases were discussed at weekly multi-
disciplinary team meetings. Oxaliplatin or irinotecan-containing regimens were considered for
stage II patients with high-risk features (tumors that were T4 or histological grade 3 or 4; peri-
tumoral lymphovascular involvement; bowel obstruction; T3 lesions with localized perforation;
positive resection margin; or perineural invasion). Chemotherapy regimens included fluoro-
pyrimidine (fluorouracil with folinic acid and capecitabine) alone or in combination with oxa-
liplatin (FOLFOX)/irinotecan (FOLFIRI).
Adjuvant radiation was used for patients with stage II and III rectal cancer. Adjuvant radia-
tion therapy was performed as follows. Fluorouracil-based chemotherapy consisted of 425 mg/
m2 of 5-fluorouracil and 20 mg/m2 of leucovorin for 5 days every 28 days for six cycles. Radia-
tion therapy was performed after the second round of chemotherapy and consisted of 50.4 to
54 Gy delivered in 28 to 30 fractions.
All surgical patients were registered in a dedicated colorectal database and followed at 3- or
6-month intervals for the first 5 years and then yearly thereafter.
Outcome measures
Time to chemotherapy was defined as the duration from surgery to initiation of adjuvant che-
motherapy. Chemotherapy delay was defined using 8 weeks as the cutoff. Postoperative com-
plications were defined as events that required additional treatment within 30 days of surgery,
based on the Clavien-Dindo classification. Conversion to open surgery was defined as comple-
tion of planned surgical procedures using a conventional laparotomy incision. Treatment-
related variables such as intensive care unit (ICU) care or blood transfusions were included in
analysis if they were required within 48 hours after primary surgery. The 48-hour limit sought
to assess intraoperative patient burdens rather than postoperative complications. We assumed
that ICU admission or transfusion within 48 hours indicated immediate surgical stress.
Chemotherapy Use and Delay
PLOS ONE | DOI:10.1371/journal.pone.0138720 September 18, 2015 3 / 12
Statistical analysis
All statistical analyses used MedCalc Statistical Software version 15.2.2 (MedCalc Software
bvba, Ostend, Belgium) and IBM SPSS Statistics for Windows, version 21.0 (IBM, Armonk,
NY, USA). Categorical variables were described by frequencies and percentages and compared
using chi-square test or Fisher's exact test as appropriate. Continuous variables were described
as mean and standard deviation and analyzed by Student’s t-test. Factors associated with use
and delay of chemotherapy were identified by logistic regression analysis. Survival analysis was
by the Kaplan-Meier method with log rank tests and the Cox proportional hazard model. A p-
value<0.05 was considered statistically significant.
Results
Details of adjuvant chemotherapy
Among 750 patients with stage II (n = 318) or III (n = 432) disease, adjuvant chemotherapy
was performed in 597 (79.6%). Among 597 patients with adjuvant chemotherapy, 31 (5.2%)
received chemotherapy 8 weeks or more after surgery. Detailed chemotherapy data are pre-
sented in Table 1.
Factors associated with no use of adjuvant chemotherapy
Based on multivariate analysis, factors associated with not receiving chemotherapy were age
80 years (hazard ratio [HR] = 5.2), American Society of Anesthesiologists (ASA) score3
(HR = 1.9), underlying cerebrovascular disease (HR = 1.7), stage II disease (HR = 2.0), presence
of postoperative complications (HR = 2.2) and ICU admission (HR = 2.4). The use of preopera-
tive chemoradiation for rectal cancer increased the use of adjuvant chemotherapy (11.4% vs.
4.6%, p = 0.012). However, in multivariate analysis, this was not an independent factor for the
use of chemotherapy (Table 2).
Factors associated with adjuvant chemotherapy delay
Based on multivariate analysis, factors affecting chemotherapy delay8 weeks were male sex
(HR = 4.2), rectal primary cancer (HR = 5.4), and the presence of postoperative complications
(HR = 2.5). The use of preoperative chemoradiation treatment for rectal cancer did not influence
adjuvant chemotherapy delay. Rates of adjuvant chemotherapy were 19.4% in patients with 8 or
more weeks and 11% in patients who received treatment in less than 8 weeks (Table 3).
Table 1. Adjuvant chemotherapy.
TNM stage
II (n = 318) III (n = 432)
N (%) N (%) P
Chemotherapy use (-) (n = 153) 83 (26.1) 70 (16.2) 0.001
(+) (n = 597) 235 (73.9) 362 (83.8)
Time to chemotherapy <8 weeks (n = 566) Fluoropyrimidine 182 (82.4) 187 (54.2) <0.001
Oxaliplatin 38 (17.2) 149 (43.2)
Irinotecan 1 (0.5) 9 (2.6)
8 weeks (n = 31) Fluoropyrimidine 11 (78.6) 15 (88.2) 0.717
Oxaliplatin 1 (7.1) 1 (5.9)
Irinotecan 2 (14.3) 1 (5.9)
doi:10.1371/journal.pone.0138720.t001
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Table 2. Factors associated with not receiving adjuvant chemotherapy (n = 750).
Univariate analysis Multivariate analysis
Chemotherapy (-) Chemotherapy (+) P HR (95% CI) P
N (%) N (%)
Age (years) <80 97 (63.4) 549 (92) <0.001 1 <0.001
80 56 (36.6) 48 (8) 5.2 (3.2–8.4)
Age subgroups 70 39 (9.9) 356 (90.1) <0.001 NA
71–75 34 (19.8) 138 (80.2)
76–80 35 (33.3) 70 (66.7)
81–85 27 (50.9) 26 (49.1)
86 18 (72) 7 (28)
Sex Male 93 (60.8) 382 (64) 0.463 NA
Female 60 (39.2) 215 (36)
BMI 30 kg/m2 9 (5.9) 18 (3) 0.089 NA
ASA score 3,4 48 (31.4) 81 (13.6) <0.001 1.9 (1.1–3.1) 0.014
Comorbidity
Diabetes 36 (23.5) 112 (18.8) 0.186 NA
Cardiovascular disease 81 (52.9) 254 (42.5) 0.021 1.2 (0.8–1.8) 0.479
Pulmonary disease 18 (11.8) 62 (10.4) 0.622 NA
Kidney disease 5 (3.3) 7 (1.2) 0.065 NA
Liver disease 4 (2.6) 19 (3.2) 0.716 NA
Cerebrovascular disease 43 (28.1) 89 (14.9) <0.001 1.7 (1.1–2.8) 0.026
Emergency (+) 7 (5.6) 24 (5.2) 0.850 NA
T4 tumor (+) 27 (17.6) 143 (24) 0.096 NA
National health insurance Medical care 22 (14.4) 59 (9.9) 0.110 NA
Region Rural (vs. urban) 35 (22.9) 167 (28) 0.205 NA
Preoperative CRT (+) 7 (4.6) 68 (11.4) 0.012 0.5 (0.2–1.2) 0.105
Location Colon 87 (56.9) 324 (54.3) 0.566 NA
Rectum 66 (43.1) 273 (45.7)
Surgical approach Open 70 (45.8) 243 (40.7) 0.259 NA
Minimally invasive 83 (54.2) 354 (59.3)
Name of operation APR, Hartmann 24 (15.7) 62 (10.4) 0.445 NA
LAR 44 (28.8) 217 (36.3)
PC 1 (0.7) 5 (0.8)
AR, LHC 42 (27.5) 154 (25.8)
TC, STC 4 (2.6) 10 (1.7)
RHC 37 (24.2) 144 (24.1)
Other 1 (0.7) 5 (0.8)
TNM II 83 (54.2) 235 (39.4) 0.001 2.0 (1.4–3.1) 0.001
III 70 (45.8) 362 (60.6) 1
Metastatic lymph node (number) 1–3 43 (61.4) 235 (64.9) 0.577 NA
4 27 (38.6) 127 (35.1)
CRM 1 mm 10 (15.2) 50 (18.3) 0.546 NA
Histologic grade G3, G4 8 (5.2) 51 (8.5) 0.174 NA
30-day complications (+) 73 (47.7) 170 (28.5) <0.001 2.2 (1.5–3.3) <0.001
Anastomotic leakage (+) 11 (7.2) 24 (4) 0.097 NA
Clavien-Dindo grade 3, 4, 5 39 (25.5) 72 (12.1) <0.001 NA
ICU admission (+) 82 (53.6) 148 (24.8) <0.001 2.4 (1.6–3.7) <0.001
Transfusion (+) 62 (40.5) 178 (29.8) 0.011 1.1 (0.7–1.8) 0.563
(Continued)
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Oncologic outcomes by use and delay of adjuvant chemotherapy
The 5-year overall survival rate was 39.4% in the no-chemotherapy group, 56.5% in the
8-week group and 80.1% in<8-week group (p<0.001) (Fig 1). The 5-year recurrence-free
survival rate was 44.8% in the no-chemotherapy group, 39.6% in the8-week delay group and
71.2% in the<8-week group (p<0.001) (Fig 2).
Prognostic survival factors by Cox proportional hazard modeling
Independent prognostic factors for overall survival included TNM III stage (HR = 2.04), che-
motherapy use (after8 week: HR = 0.39 and within<8 weeks: HR = 0.22). Independent
prognostic factors for recurrence-free survival were TNM III stage (HR = 2.26) and chemother-
apy use (within<8 weeks, HR = 0.35) (Table 4).
Discussion
The major findings of this study were that different factors affected lack of chemotherapy
(older age, ASA score, underlying cerebrovascular disease, stage II disease, postoperative com-
plications, and ICU admission) and delay of chemotherapy (male, rectal cancer, and postopera-
tive complications), with the exception of postoperative complications. Both lack of
chemotherapy and delay8 weeks negatively influenced overall and recurrence-free survival.
Timely initiation of chemotherapy (<8 weeks) was a favorable prognostic factor for overall
and recurrence-free survival.
Factors associated with the use of adjuvant chemotherapy
Various factors were associated with the use of adjuvant chemotherapy. Older patients receive
adjuvant chemotherapy less often than younger patients [12, 13]. Dobie et al.[14] found that
the rate of adjuvant chemotherapy decreased with advanced age; in their study, 78.9% of
patients in the 66- to 70-year-old group received chemotherapy compared to 71.2% in the 71-
to 75-year-old group, 56.3% in the 76- to 80-year-old group, 29.8% in the 81- to 85-year-old
group and 8.1% in the 86-year-or-older group. We observed the same pattern of decline in che-
motherapy use with increasing age.
Patient comorbidity is also related to chemotherapy use. Most studies that measure this out-
come use the Charlson comorbidity index, with a higher index score associated with a lower
rate of chemotherapy use [13, 15]. Gross et al.[16] demonstrated that chronic illnesses such as
congestive heart failure, chronic obstructive pulmonary disease, and diabetes influence
Table 2. (Continued)
Univariate analysis Multivariate analysis
Chemotherapy (-) Chemotherapy (+) P HR (95% CI) P
N (%) N (%)
Operative time 300 min 9 (7.3) 52 (11.3) 0.191 NA
Open conversion (+) 11 (13.3) 35 (9.9) 0.368 NA
BMI, body mass index; ASA, American Society of Anesthesiologists; CRT, chemoradiation; APR, abdominoperineal resection; LAR, low anterior resection;
PC, proctocolectomy; AR, anterior resection; LHC, left hemicolectomy; TC, total colectomy; STC, subtotal colectomy; RHC, right hemicolectomy; TNM,
tumor-node-metastasis; CRM, circumferential resection margin; ICU, intensive care unit; HR, hazard ratio; CI, conﬁdence interval; NA, not applied
doi:10.1371/journal.pone.0138720.t002
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Table 3. Factors associated with a8-week delay to adjuvant chemotherapy (n = 597).
Univariate Multivariate
8 weeks <8 weeks P HR (95%CI) P
N (%) N (%)
Age (years) <80 29 (93.5) 520 (91.9) 0.738 NA
80 2 (6.5) 46 (8.1)
Age subgroups 70 19 (5.3) 337 (94.7) NA
71–75 9 (6.5) 129 (93.5)
76–80 2 (2.9) 68 (97.1)
81–85 1 (3.8) 25 (96.2)
86 0 (0) 7 (100)
Sex Female 3 (9.7) 212 (37.5) 0.002 1 0.022
Male 28 (90.3) 354 (62.5) 4.2 (1.2–14.2)
BMI 30 kg/m2 0 (0) 18 (3.2) 0.313 NA
ASA score 3,4 5 (16.1) 76 (13.4) 0.669 NA
Comorbidity
Diabetes 6 (19.4) 106 (18.7) 0.931 NA
Cardiovascular disease 12 (38.7) 242 (42.8) 0.657 NA
Pulmonary disease 5 (16.1) 57 (10.1) 0.282 NA
Kidney disease 0 (0) 7 (1.2) 0.533 NA
Liver disease 2 (6.5) 17 (3) 0.287 NA
Cerebrovascular disease 8 (25.8) 81 (14.3) 0.08 NA
Emergency (+) 1 (4.5) 23 (5.3) 0.885 NA
T4 tumor (+) 11 (35.5) 132 (23.3) 0.122 NA
National health insurance Medical care 4 (12.9) 55 (9.7) 0.563 NA
Region Rural (vs. urban) 10 (32.3) 157 (27.7) 0.585 NA
Preoperative CRT (+) 6 (19.4) 62 (11) 0.152 NA
Location Colon 5 (16.1) 319 (56.4) <0.001 1 0.001
Rectum 26 (83.9) 247 (43.6) 5.4(2–14.5)
Surgical approach Open 17 (54.8) 226 (39.9) 0.1 NA
Minimally invasive 14 (45.2) 340 (60.1)
Name of operation APR, Hartmann 5 (16.1) 57 (10.1) 0.001 NA
LAR 22 (71) 195 (34.5)
PC 0 (0) 5 (0.9)
AR, LHC 2 (6.5) 152 (26.9)
TC, STC 0 (0) 10 (1.8)
RHC 2 (6.5) 142 (25.1)
Other 0 (0) 5 (0.9)
TNM II 14 (45.2) 221 (39) 0.497 NA
III 17 (54.8) 345 (61)
Metastatic lymph node (number) 1–3 10 (65.2) 225 (58.8) 0.590 NA
4 7 (34.8) 120 (41.2)
CRM 1 mm 5 (19.2) 45 (18.2) 0.899 NA
Histologic grade G3, G4 0 (0) 51 (9) 0.081 NA
30-day complications (+) 18 (58.1) 152 (26.9) <0.001 2.5 (1.1–5.4) 0.021
Anastomotic leakage (+) 8 (25.8) 16 (2.8) <0.001 NA
Clavien-Dindo grade 3, 4, 5 12 (38.7) 60 (10.6) <0.001 NA
ICU admission (+) 8 (25.8) 140 (24.7) 0.893 NA
(Continued)
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decreased use of adjuvant chemotherapy. In this study, underlying cerebrovascular disease was
a negative predictor for chemotherapy use.
Patient functional status is another important factor when considering chemotherapy use.
Age, comorbidity, and functional status are closely related to preoperative health status.
Although data are scarce on functional status and use of chemotherapy in an adjuvant setting,
patients with stage IV disease and diminished performance status are less likely to receive palli-
ative chemotherapy [17]. As a measure of functional status, we used ASA score, which is a
widely adopted grading system for predicting postoperative morbidity and mortality. We
observed that ASA scores of 3 and 4 were independent negative predictors for use of
chemotherapy.
Tumor histopathology is related to chemotherapy use. Greater numbers of metastatic
lymph nodes are associated with more frequent use of chemotherapy[13], likely due to
increased consultation needs[18]. Surgical and medical oncologists tend to be more active in
recommending chemotherapy in patients with higher-risk tumors. In our study, the number of
metastatic nodes was not related to use of chemotherapy, but stage III disease was associated
with more frequent use of chemotherapy compared to stage II.
Table 3. (Continued)
Univariate Multivariate
8 weeks <8 weeks P HR (95%CI) P
N (%) N (%)
Transfusion (+) 15 (48.4) 163 (28.8) 0.02 2 (0.9–4.3) 0.077
Operative time 300 min 3 (13.6) 49 (11.2) 0.723 NA
Open conversion (+) 5 (35.7) 30 (8.8) 0.001 NA
BMI, body mass index; ASA, American Society of Anesthesiologists; CRT, chemoradiation; APR, abdominoperineal resection; LAR, low anterior resection;
PC, proctocolectomy; AR, anterior resection; LHC, left hemicolectomy; TC, total colectomy; STC, subtotal colectomy; RHC, right hemicolectomy; TNM,
tumor-node-metastasis; CRM, circumferential resection margin; ICU, intensive care unit; HR, hazard ratio; CI, conﬁdence interval; NA, not applied
doi:10.1371/journal.pone.0138720.t003
Fig 1. Overall survival according to use of adjuvant chemotherapy use. Five-year rates by group: 39.4%
no chemotherapy; 56.5% delay8 weeks; 80.1% <8 weeks (p<0.001).
doi:10.1371/journal.pone.0138720.g001
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Postoperative complications result in prolonged patient recovery, longer hospital stays, and
a higher likelihood of readmission [19, 20]. Accordingly, the presence of postoperative compli-
cations is associated with less frequent use of chemotherapy, [21] as was confirmed in this
study.
Hospital or physician factors may also affect chemotherapy use. This study was performed
in a single tertiary referral center, which allowed good control of systemic factors. In our hospi-
tal, adjuvant treatment plans were based on final pathology reports and decided after surgery
in weekly meetings of multidisciplinary teams. The treating oncologists explained the overall
adjuvant treatment plan and estimated the prognosis of the patient. Patients and family then
chose whether or not to receive adjuvant chemotherapy and some refused further treatment.
We were unable to evaluate the frequency of patient refusal. In addition, socioeconomic status
and race/ethnicity, marital status, area of residence, and income influence the use of chemo-
therapy [5, 12, 22, 23].
Fig 2. Recurrence-free survival according to use of adjuvant chemotherapy use. Five-year rates by
group: 44.8% no chemotherapy; 39.6% delay8 weeks; 71.2% <8 weeks (p<0.001).
doi:10.1371/journal.pone.0138720.g002
Table 4. Prognostic factors for survival on Cox proportional hazardmodeling.
Overall survival Recurrence-free survival
HR (95% CI) P HR (95% CI) P
Use of and time to chemotherapy
(No use) Reference Reference
(8 weeks) 0.39 (0.2–0.78) 0.008 0.73 (0.4–1.33) 0.301
(<8 weeks) 0.22 (0.15–0.32) <0.001 0.35 (0.24–0.5) <0.001
TNM (III vs. II) 2.04 (1.44–2.9) <0.001 2.26 (1.65–3.09) <0.001
Age (80 vs. <80 years) 1.38 (0.9–2.12) 0.142 0.97 (0.64–1.48) 0.896
30-day complications (+ vs.-) 1.29 (0.92–1.79) 0.139 1.18 (0.87–1.59) 0.280
ASA score (3,4 vs. 1,2) 1.24 (0.83–1.85) 0.287 1.11 (0.76–1.61) 0.605
HR, hazard ratio; CI, conﬁdence interval; TNM, tumor-node-metastasis; ASA, American Society of Anesthesiologists
doi:10.1371/journal.pone.0138720.t004
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Factors associated with delay of adjuvant chemotherapy
Older age, black race, prolonged postoperative recovery, severe comorbidity, advanced histo-
logic grade, and unmarried status are associated with delay of adjuvant chemotherapy [19, 22,
24]. In this study, presence of postoperative complications was an independent predictor for
chemotherapy delay. In the delayed-chemotherapy group, 90.3% were men (vs. 62.5% in the
nondelayed group), 83.9% had rectal cancer (vs. 43.6% in the nondelayed group), 58.1% experi-
enced postoperative complications (vs. 26.9% in the nondelayed group) and 25.8% had anasto-
motic leakage (vs. 2.8% in the nondelayed group). These factors appeared to be related to
surgical outcomes. Male sex is a well-known risk factor for anastomotic leakage after rectal can-
cer surgery [25]. Thus, surgeons should be aware of the detrimental effect of postoperative
complications on time to chemotherapy initiation.
Institutional delay between interdepartmental consultations has been suggested as another
factor related to chemotherapy delay [6]. In this study, all included patients underwent surgery
in our hospital and were discussed at multidisciplinary team meetings. Accordingly, the effect
of institutional delay was likely to be small.
Oncologic outcomes related to use and delay of chemotherapy
Adjuvant chemotherapy improves overall and recurrence-free rates of survival in stage II and III
colorectal cancer[12]. One meta-analysis showed that more than 8 weeks of delay to adjuvant
chemotherapy in stage III colorectal cancer worsened overall survival [22]. However, Zeig-
Owens et al.[23] demonstrated that a chemotherapy delay of more than 45 days was not associ-
ated with survival of patients with stage II and III colon cancer. Additional controversies are over
the definition of delay, which has been defined as 45 days[23, 26], 8 weeks[27–29], and 3 months
[19] in various studies. In this study, delay of chemotherapy8 weeks showed oncologic benefits
in terms of overall survival when compared to no chemotherapy, but no benefits in recurrence-
free survival. Timely initiation of chemotherapy in<8 weeks was a favorable prognostic factor
for overall and recurrence-free survival. Postoperative complications are suggested to be risk fac-
tors for inferior oncologic outcomes[30]. In this study, surgical complications were associated
with lack of and delay of chemotherapy, but were not a prognostic factor. This study used 8
weeks as the cutoff for chemotherapy delay. This decision was based on Health Insurance Review
Assessment Service of South Korea claims data on time to chemotherapy initiation in patients
with colorectal cancer. In Korea, if patients do not receive adjuvant chemotherapy or undergo
chemotherapy after more than 8 weeks, treating physicians must notify a government agency.
This study was limited by its single-center, retrospective design. In addition, data regarding
chemotherapy dose reduction or discontinuation were not available. Although all medical rec-
ords were reviewed, we acknowledge that some treatment-related events such as ICU admis-
sion or transfusion could have been missed.
In summary, we identified factors associated with not receiving chemotherapy or experienc-
ing a8-week delay to chemotherapy in an adjuvant setting after surgery for stage II or III
colorectal cancer. Among the factors investigated, the presence of postoperative complications
correlated with both not receiving and delay of chemotherapy. Timely initiation of chemother-
apy (<8 weeks postoperative) was a favorable prognostic factor for overall and recurrence-free
survival. To increase the proportion of patients receiving chemotherapy and timely initiation
of chemotherapy, surgical complications should be minimized after curative resection.
Acknowledgments
We would like to thank professor Jee Hyun Kong (Department of Hematology-Oncology),
Hyun Soo Kim (Department of Internal Medicine), Jong Young Lee (Department of Radiation
Chemotherapy Use and Delay
PLOS ONE | DOI:10.1371/journal.pone.0138720 September 18, 2015 10 / 12
Oncology), and Seung Whan Cha (Department of Radiology) for their insightful comments on
this manuscript and support in multidisciplinary team meetings. This manuscript was pre-
sented at the 2015 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
(January 15–17, 2015, in San Francisco, California). Our Institutional Review Board has ethical
restrictions about data distribution; these restrictions are in line with the approved consent
procedure. All data are available upon request. Interested researchers may submit data requests
to the corresponding author.
Author Contributions
Conceived and designed the experiments: YWK IYK. Performed the experiments: BRK YWK.
Analyzed the data: BRK YWK. Contributed reagents/materials/analysis tools: YWK BRK.
Wrote the paper: YWK IYK.
References
1. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, TophamC, et al. Improved overall survival with
oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the
MOSAIC trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology.
2009; 27(19):3109–16. Epub 2009/05/20. doi: 10.1200/jco.2008.20.6771 PMID: 19451431.
2. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus
observation in patients with colorectal cancer: a randomised study. Lancet. 2007; 370(9604):2020–9.
Epub 2007/12/18. doi: 10.1016/s0140-6736(07)61866-2 PMID: 18083404.
3. Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analy-
sis. Diseases of the colon and rectum. 1997; 40(1):35–41. Epub 1997/01/01. PMID: 9102259.
4. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survi-
vorship statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(4):252–71. doi: 10.3322/caac.
21235 PMID: 24890451.
5. Etzioni DA, El-Khoueiry AB, Beart RW Jr. Rates and predictors of chemotherapy use for stage III colon
cancer: a systematic review. Cancer. 2008; 113(12):3279–89. Epub 2008/10/28. doi: 10.1002/cncr.
23958 PMID: 18951522.
6. Biagi JJ, Raphael MJ, MackillopWJ, KongW, KingWD, Booth CM. Association between time to initia-
tion of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analy-
sis. JAMA: the journal of the American Medical Association. 2011; 305(22):2335–42. Epub 2011/06/07.
doi: 10.1001/jama.2011.749 PMID: 21642686.
7. National Comprehensive Cancer Network. Rectal cancer (Version 1.2015) [cited 2015 January 7].
Available from: http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
8. National Comprehensive Cancer Network. Colon cancer (Version 2.2015) [cited 2015 January 7]. Avail-
able from: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
9. Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer:
improved survival in stage II and III. British journal of cancer. 2001; 85(10):1437–43. Epub 2001/11/27.
doi: 10.1054/bjoc.2001.2117 PMID: 11720425; PubMed Central PMCID: PMCPmc2363941.
10. Wolmark N, Rockette H, Fisher B, WickerhamDL, Redmond C, Fisher ER, et al. The benefit of leucov-
orin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from
National Surgical Adjuvant Breast and Bowel Project protocol C-03. Journal of clinical oncology: official
journal of the American Society of Clinical Oncology. 1993; 11(10):1879–87. Epub 1993/10/01. PMID:
8410113.
11. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting
observational studies. Lancet. 2007; 370(9596):1453–7. Epub 2007/12/08. doi: 10.1016/s0140-6736
(07)61602-x PMID: 18064739.
12. Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD, et al. Use of adjuvant
chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. Journal of clini-
cal oncology: official journal of the American Society of Clinical Oncology. 2003; 21(7):1293–300. Epub
2003/03/29. PMID: 12663717.
13. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage
III colon cancer. Journal of the National Cancer Institute. 2001; 93(11):850–7. Epub 2001/06/08. PMID:
11390534.
Chemotherapy Use and Delay
PLOS ONE | DOI:10.1371/journal.pone.0138720 September 18, 2015 11 / 12
14. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, BarlowW. Completion of therapy by
Medicare patients with stage III colon cancer. Journal of the National Cancer Institute. 2006; 98
(9):610–9. Epub 2006/05/04. doi: 10.1093/jnci/djj159 PMID: 16670386; PubMed Central PMCID:
PMCPmc3124351.
15. McGory ML, Zingmond DS, Sekeris E, Bastani R, Ko CY. A patient's race/ethnicity does not explain the
underuse of appropriate adjuvant therapy in colorectal cancer. Diseases of the colon and rectum. 2006;
49(3):319–29. Epub 2006/02/14. doi: 10.1007/s10350-005-0283-6 PMID: 16475031.
16. Gross CP, McAvay GJ, Guo Z, Tinetti ME. The impact of chronic illnesses on the use and effectiveness
of adjuvant chemotherapy for colon cancer. Cancer. 2007; 109(12):2410–9. Epub 2007/05/19. doi: 10.
1002/cncr.22726 PMID: 17510973.
17. Kim YW, Kim IY. The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV
Colorectal Cancer. Ann Coloproctol. 2013; 29(2):44–54. Epub 2013/05/24. doi: 10.3393/ac.2013.29.2.
44 PubMed Central PMCID: PMCPmc3659242. PMID: 23700570
18. Luo R, Giordano SH, Freeman JL, Zhang D, Goodwin JS. Referral to medical oncology: a crucial step
in the treatment of older patients with stage III colon cancer. The oncologist. 2006; 11(9):1025–33.
Epub 2006/10/13. doi: 10.1634/theoncologist.11-9-1025 PMID: 17030645; PubMed Central PMCID:
PMCPmc1913211.
19. CheungWY, Neville BA, Earle CC. Etiology of delays in the initiation of adjuvant chemotherapy and
their impact on outcomes for Stage II and III rectal cancer. Diseases of the colon and rectum. 2009; 52
(6):1054–63; discussion 64. doi: 10.1007/DCR.0b013e3181a51173 PMID: 19581846.
20. Hendren S, Birkmeyer JD, Yin H, Banerjee M, Sonnenday C, Morris AM. Surgical complications are
associated with omission of chemotherapy for stage III colorectal cancer. Diseases of the colon and
rectum. 2010; 53(12):1587–93. doi: 10.1007/DCR.0b013e3181f2f202 PMID: 21178851.
21. Baldwin LM, Dobie SA, Billingsley K, Cai Y, Wright GE, Dominitz JA, et al. Explaining black-white differ-
ences in receipt of recommended colon cancer treatment. Journal of the National Cancer Institute.
2005; 97(16):1211–20. Epub 2005/08/18. doi: 10.1093/jnci/dji241 PMID: 16106026; PubMed Central
PMCID: PMCPmc3138542.
22. Des Guetz G, Nicolas P, Perret GY, Morere JF, Uzzan B. Does delaying adjuvant chemotherapy after
curative surgery for colorectal cancer impair survival? A meta-analysis. European journal of cancer
(Oxford, England: 1990). 2010; 46(6):1049–55. Epub 2010/02/09. doi: 10.1016/j.ejca.2010.01.020
PMID: 20138505.
23. Zeig-Owens R, Gershman ST, Knowlton R, Jacobson JS. Survival and time interval from surgery to
start of chemotherapy among colon cancer patients. Journal of registry management. 2009; 36(2):30–
41; quiz 61–2. Epub 2009/08/22. PMID: 19694115.
24. Hershman D, Hall MJ, Wang X, Jacobson JS, McBride R, Grann VR, et al. Timing of adjuvant chemo-
therapy initiation after surgery for stage III colon cancer. Cancer. 2006; 107(11):2581–8. Epub 2006/11/
02. doi: 10.1002/cncr.22316 PMID: 17078055.
25. LawWI, Chu KW, Ho JW, Chan CW. Risk factors for anastomotic leakage after low anterior resection
with total mesorectal excision. Am J Surg. 2000; 179(2):92–6. Epub 2000/04/25. PMID: 10773140.
26. Bayraktar UD, Chen E, Bayraktar S, Sands LR, Marchetti F, Montero AJ, et al. Does delay of adjuvant
chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? Cancer.
2011; 117(11):2364–70. Epub 2011/06/01. doi: 10.1002/cncr.25720 PMID: 24048783.
27. Ahmed S, Ahmad I, Zhu T, Arnold FP, Faiz Anan G, Sami A, et al. Early discontinuation but not the tim-
ing of adjuvant therapy affects survival of patients with high-risk colorectal cancer: a population-based
study. Diseases of the colon and rectum. 2010; 53(10):1432–8. Epub 2010/09/18. doi: 10.1007/DCR.
0b013e3181e78815 PMID: 20847626.
28. Chau I, Norman AR, Cunningham D, Tait D, Ross PJ, Iveson T, et al. A randomised comparison
between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluoro-
uracil as adjuvant treatment in colorectal cancer. Annals of oncology: official journal of the European
Society for Medical Oncology / ESMO. 2005; 16(4):549–57. Epub 2005/02/08. doi: 10.1093/annonc/
mdi116 PMID: 15695501.
29. Czaykowski PM, Gill S, Kennecke HF, Gordon VL, Turner D. Adjuvant chemotherapy for stage III colon
cancer: does timing matter? Diseases of the colon and rectum. 2011; 54(9):1082–9. Epub 2011/08/10.
doi: 10.1097/DCR.0b013e318223c3d6 PMID: 21825887.
30. LawWL, Choi HK, Lee YM, Ho JW. The impact of postoperative complications on long-term outcomes
following curative resection for colorectal cancer. Annals of surgical oncology. 2007; 14(9):2559–66.
Epub 2007/05/25. doi: 10.1245/s10434-007-9434-4 PMID: 17522945.
Chemotherapy Use and Delay
PLOS ONE | DOI:10.1371/journal.pone.0138720 September 18, 2015 12 / 12
